In a 64‑year‑old man with rheumatoid arthritis treated with tocilizumab, what differential diagnosis is suggested by long‑standing low serum globulins, thrombocytopenia (~100 × 10⁹/L), mild leukopenia (~4 × 10⁹/L), normal hemoglobin and hematocrit, and a slowly increasing macrocytosis (MCV ~101 fL) with rising MCH and stable MCHC?

Differential Diagnosis: Myelodysplastic Syndrome (MDS) with Tocilizumab-Related Cytopenias

The most critical diagnosis to exclude in this patient is myelodysplastic syndrome (MDS), given the combination of long-standing low globulins, mild cytopenias (thrombocytopenia and leukopenia), and progressive macrocytosis, despite the currently preserved hemoglobin—all occurring in the context of chronic inflammatory disease and immunosuppressive therapy.

Primary Diagnostic Considerations

1. Myelodysplastic Syndrome (MDS) - Highest Priority

This is the most concerning diagnosis that requires immediate evaluation:

• Key supporting features:

  • Progressive macrocytosis (MCV 101.3 and rising) with rising MCH is a hallmark of dysplastic erythropoiesis 1
  • Mild thrombocytopenia (100,000) and leukopenia (4,000) represent multilineage cytopenias
  • Long-standing RA with chronic inflammation is a recognized risk factor for MDS development 2
  • Age 64 years falls within typical MDS demographic
  • Low globulins may reflect immune dysregulation associated with MDS

• Critical action required: Bone marrow aspiration and biopsy with cytogenetics is mandatory to exclude MDS 1. The NCCN guidelines emphasize that patients with unexplained cytopenias and macrocytosis require bone marrow evaluation, particularly when multiple lineages are affected.

• Important caveat: The currently normal hemoglobin (16 g/dL) and hematocrit (46%) do NOT exclude MDS. Lower-risk MDS can present with isolated thrombocytopenia or leukopenia before anemia develops 1. The progressive nature of the macrocytosis is particularly concerning.

2. Tocilizumab-Induced Hematologic Effects - Secondary Consideration

Tocilizumab causes predictable hematologic changes that overlap with this presentation:

• Expected tocilizumab effects 3:

  • Neutropenia occurs predictably, with nadir at 3-5 days post-dose, then recovery
  • Decreases in absolute neutrophil counts are dose-dependent
  • Hemoglobin typically increases with tocilizumab due to IL-6 blockade reducing hepcidin

• Why this doesn't fully explain the picture:

  • Tocilizumab-induced neutropenia is typically transient and cyclical, not sustained 3
  • The progressive macrocytosis is NOT a recognized effect of tocilizumab
  • Thrombocytopenia can occur but is usually mild and transient 3
  • The long-standing low globulins preceded tocilizumab (implied by "long-standing")

3. Hypogammaglobulinemia - Contributing Factor

The long-standing low serum globulins warrant specific attention:

• While hypogammaglobulinemia is more commonly associated with rituximab than tocilizumab 4, chronic RA itself can cause immune dysregulation
• This may represent underlying immune dysfunction predisposing to MDS 2
• Check quantitative immunoglobulins (IgG, IgA, IgM) to characterize the deficiency

Diagnostic Algorithm

Immediate workup (within 1-2 weeks):

1. Bone marrow aspiration and biopsy with:

   • Morphologic assessment for dysplasia
   • Cytogenetics (karyotype)
   • FISH panel for MDS
   • Flow cytometry
   • Consider molecular testing (NGS panel for myeloid mutations)

2. Laboratory evaluation:

   • Vitamin B12 and folate levels (macrocytosis differential)
   • Thyroid function tests (TSH)
   • Liver function tests
   • Reticulocyte count
   • Peripheral blood smear review for dysplastic features
   • Quantitative immunoglobulins
   • Serum erythropoietin level (prognostic for MDS treatment) 1

3. Review medication history:

   • Duration and cumulative dose of methotrexate (causes macrocytosis)
   • Other potential marrow-suppressive agents
   • Alcohol use history

Risk Stratification if MDS Confirmed

If bone marrow confirms MDS, risk stratification using IPSS-R or WPSS is essential 1:

• Lower-risk MDS (IPSS low/int-1): Consider erythropoiesis-stimulating agents if anemia develops, immunosuppressive therapy if hypocellular marrow, or clinical trial
• Higher-risk MDS (IPSS int-2/high): Requires hypomethylating agents (azacitidine/decitabine) or allogeneic transplant evaluation 1

Management Considerations for Tocilizumab

Do NOT automatically discontinue tocilizumab until MDS is confirmed or excluded:

• If MDS is excluded and cytopenias are mild and stable, tocilizumab can often be continued with close monitoring 3
• If MDS is confirmed, tocilizumab may actually be beneficial—one case report demonstrated successful treatment of RA with MDS using tocilizumab, particularly when IL-6 levels are elevated 2
• Monitor CBC every 4-8 weeks while on tocilizumab 3

Critical Pitfalls to Avoid

1. Do not attribute progressive macrocytosis to tocilizumab alone—this is not a recognized drug effect and warrants bone marrow evaluation
2. Do not be falsely reassured by normal hemoglobin—MDS can present with isolated thrombocytopenia or leukopenia before anemia develops 1
3. Do not delay bone marrow biopsy for vitamin B12/folate replacement trials—the combination of multilineage cytopenias with progressive macrocytosis requires definitive evaluation
4. Do not assume methotrexate-induced macrocytosis without excluding MDS, especially with concurrent cytopenias